DeutschNewstral
Article
jdsupra.com on 2020-12-02 21:45
Innovators challenge final PMPRB Guidelines in new Federal Court application
Related news
- PMPRB posts submissions from Guidelines consultation; Federal Court challenge of amended Regulations rescheduledjdsupra.com
- Few significant changes made in final PMPRB Guidelinesjdsupra.com
- Final PMPRB Guidelines Releasedjdsupra.com
- PMPRB adopts Amended Interim Guidance pending release of new guidelinesjdsupra.com
- PMPRB Update: new consultation on PMPRB Guidelines, including revised international price testsjdsupra.com
- New PMPRB Guidelines will not be implemented January 1, 2023jdsupra.com
- 2021 PMPRB Annual Reportjdsupra.com
- PMPRB News: “significant changes” to be made to draft pricing Guidelinesjdsupra.com
- PMPRB publishes scoping paper for consultation on guidelines, and invites stakeholder feedbackjdsupra.com
- Draft revised PMPRB Guidelines released for comment by December 5, 2022jdsupra.com
- PMPRB news: Upcoming roundtable as first phase of new guidelines consultation, two new appointmentsjdsupra.com
- PMPRB proposes to modify Guidelines definition of "gap medicine" to include medicines sold by July 1, 2021jdsupra.com
- Federal Court of Appeal dismisses appeal challenging amended basket of comparator countries in PMPRB Regulationsjdsupra.com
- PMPRB publishes annual Meds Pipeline Monitor reportjdsupra.com
- PMPRB releases three new NPDUIS reportsjdsupra.com
- PMPRB Update: Jurisdiction extends to CSPs effective June 30; coming into force of Patented Medicines Regulations and Guidelines delayed to January 2022jdsupra.com
- Federal Court finds PMPRB reasonably concluded Galderma’s patent claiming 0.3% adapalene “pertained to” 0.1% adapalene DIFFERINjdsupra.com
- PMPRB releases revised draft Guidelinesjdsupra.com
- V$160,000+ on the line for young innovators with Ingenious+ challengevoiceonline.com
- PMPRB finds ultra-rare drug PROCYSBI is excessively pricedjdsupra.com